Skip to main content
Fig. 6 | Journal of Ovarian Research

Fig. 6

From: Ghrelin enhances cisplatin sensitivity in HO-8910 PM human ovarian cancer cells

Fig. 6

Inhibitors of p38 enhanced sensitivity of HO-8910 PM to cisplatin. A-B MTT assay of HO-8910 PM under U0126 (5 μM) or SB202190 (5 μM) treatment in the presence or absence of cisplatin (1 μg/ml). C-F Alterations of the apoptosis measured in HO-8910 PM after treatment with U0126 (C-D) or SB202190 (E-F), cisplatin and the combination of inhibitors with cisplatin. G-J The cell cycle distribution of HO-8910 PM after treatment with U0126 (G-H) or SB202190 (I-J), cisplatin and the combination of inhibitors with cisplatin. Data are shown as the mean ± SD from three independent experiments. * p < 0.05, ** p < 0.01, ***p < 0.001 versus control group. $$$ p < 0.001 versus DDP group

Back to article page